ETH Zurich glucose-reducing implant development

Researchers at ETH Zurich have developed an experimental wireless implant, named ECHO (Electrocatalytic Closed-Loop Health Optimization), designed to treat type 2 diabetes and obesity. The device utilizes electrocatalysis to convert excess glucose into gluconate, which is then largely excreted through the kidneys.

The system operates via a closed-loop mechanism where a glucose sensor communicates with a smartphone or smartwatch via Bluetooth. When glucose levels exceed a specific threshold, the electronic unit activates a catalyst composed of graphite felt with gold nanostructures and platinum particles. The system is designed to shut off automatically once levels return to the desired range to prevent hypoglycemia.

In laboratory trials involving mice with type 2 diabetes and obesity, the technology successfully stabilized glucose levels over a six-week period, helped reduce weight by approximately 10%, and improved certain blood lipid values. While these results are promising, researchers note that the technology has not yet been tested in humans. Questions remain regarding whether the implant can safely and effectively process glucose at a scale sufficient for human clinical benefit, given the metabolic and immunological differences between species.